Filtered By:
Source: American Heart Journal
Education: Study
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 295 results found since Jan 2013.
Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients–Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial
ConclusionCAMELLIA-TIMI 61 is investigating the safety and efficacy of lorcaserin for MACEs and conversion to diabetes in overweight or obese patients with established cardiovascular disease or multiple cardiovascular risk factors.
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research
A clinical decision instrument to predict 30-day death & cardiovascular hospitalizations following an emergency department visit for atrial fibrillation: The atrial fibrillation in the emergency room, part 2 (AFTER2) study
ConclusionsUsing a population-based sample, we derived and validated a tool that predicts the risk of early death and re-hospitalization for a cardiovascular reason in emergency department AF patients. The tool can offer information to managing physicians about the risk of death and re-hospitalization AF patients seen in the in emergency department, as well as identify patient groups for future targeted interventions aimed at preventing these outcomes.Graphical AbstractThe Atrial Fibrillation in the Emergency Room, part 2 (AFTER2) Study
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research
I-CARE randomized clinical trial integrating depression and acute coronary syndrome care in low-resource hospitals in China: Design and rationale
Publication date: August 2018 Source:American Heart Journal, Volume 202 Author(s): Shenshen Li, James A. Blumenthal, Chuan Shi, Danielle Millican, Xian Li, Xin Du, Anushka Patel, Pei Gao, Elizabeth Delong, Pallab K. Maulik, Runlin Gao, Xin Yu, Yangfeng Wu Depression and acute coronary syndromes (ACS) are both common public health challenges. Patients with ACS often develop depression, which in turn adversely affects prognosis. Low-cost, sustainable, and effective service models that integrate depression care into the management of ACS patients to reduce depression and improve ACS outcomes are critically needed. Integratin...
Source: American Heart Journal - June 20, 2018 Category: Cardiology Source Type: research
A clinical decision instrument to predict 30-day death & amp; cardiovascular hospitalizations following an emergency department visit for atrial fibrillation: The atrial fibrillation in the emergency room, part 2 (AFTER2) study
Conclusions Using a population-based sample, we derived and validated a tool that predicts the risk of early death and re-hospitalization for a cardiovascular reason in emergency department AF patients. The tool can offer information to managing physicians about the risk of death and re-hospitalization AF patients seen in the in emergency department, as well as identify patient groups for future targeted interventions aimed at preventing these outcomes. Graphical abstract
Source: American Heart Journal - June 13, 2018 Category: Cardiology Source Type: research
ALLiance for sEcondary PREvention after an acute coronary syndrome. The ALLEPRE trial: a multicentre fully nurse-coordinated intensive intervention programme
Publication date: Available online 12 June 2018 Source:American Heart Journal Author(s): Giorgia Paoli, Notarangelo Maria Francesca, Maria Mattioli, Rachele La Sala, Chiara Foà, Emilia Solinas, Sara Fusco, Cristian Fava, Caterina Caminiti, Giovanna Artioli, Giovanna Maria Pelà, Elisabetta Dall’Aglio, Antonio Manari, Stefano Tondi, Antonio Rizzo, Gaia Trapolin, Giampiero Patrizi, Stefano Cappelli, Giovanni Quinto Villani, Massimo Piepoli, Gianni Zobbi, Elisa Nicosia, Diego Ardissino The main objective of cardiovascular disease prevention is to reduce morbidity and mortality by promoting a healthy lifestyle, reducing ri...
Source: American Heart Journal - June 12, 2018 Category: Cardiology Source Type: research
Revival of transcatheter PFO closure: A meta-analysis of randomized controlled trials - impact of shunt size and age
Conclusion According to our meta-analysis TPC plus antiplatelets was superior in terms of stroke prevention when compared to Med-Tx. Furthermore, patients with moderate to severe shunts and those younger than 45 years of age were found to benefit most from TPC.
Source: American Heart Journal - May 26, 2018 Category: Cardiology Source Type: research
International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design
Conclusions ISCHEMIA will provide new scientific evidence regarding whether an invasive management strategy improves clinical outcomes when added to optimal medical therapy in patients with SIHD and moderate or severe ischemia.
Source: American Heart Journal - May 26, 2018 Category: Cardiology Source Type: research
I-CARE randomized clinical trial integrating depression and acute coronary syndrome Care in low Resource Hospitals in China: Design and rationale
Publication date: Available online 21 May 2018 Source:American Heart Journal Author(s): Shenshen Li, James A. Blumenthal, Chuan Shi, Danielle Millican, Xian Li, Xin Du, Anushka Patel, Pei Gao, Elizabeth Delong, Pallab K. Maulik, Runlin Gao, Xin Yu, Yangfeng Wu Depression and acute coronary syndromes (ACS) are both common public health challenges. Patients with ACS often develop depression, which in turn adversely affects prognosis. Low-cost, sustainable, and effective service models that integrated depression care into the management of ACS patients to reduce depression and improve ACS outcomes are critically needed. Inte...
Source: American Heart Journal - May 22, 2018 Category: Cardiology Source Type: research
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE) –TIMI 58 Trial
Conclusion The DECLARE–TIMI 58 trial is testing the hypotheses that dapagliflozin is safe (does not increase) and may reduce the occurrence of major CV events. DECLARE–TIMI 58 is the largest study to address this question with an SGLT-2 inhibitor in patients with T2DM and with established CV disease and without CV disease but with multiple risk factors.
Source: American Heart Journal - May 8, 2018 Category: Cardiology Source Type: research
Randomized placebo controlled trial evaluating the safety and efficacy of single low-dose intracoronary insulin-like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI)
Conclusions In this pilot trial, low-dose IGF1, given after optimal mechanical reperfusion in STEMI, is safe but does not improve LVEF. However, there is a signal for a dose-dependent benefit on post-MI remodeling that may warrant further study.
Source: American Heart Journal - May 8, 2018 Category: Cardiology Source Type: research
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF
Conclusion The use of rivaroxaban compared with warfarin was associated with a higher risk of stroke and bleeding in patients with polyvascular disease enrolled in ROCKET AF. Further studies are needed to understand the optimal management of this high-risk population.
Source: American Heart Journal - May 8, 2018 Category: Cardiology Source Type: research
Revival of Transcatheter PFO Closure: A meta-analysis of randomized controlled trials
Conclusion According to our meta-analysis TPC plus antiplatelets was superior in terms of stroke prevention when compared to Med-Tx. Furthermore, patients with moderate to severe shunts and those younger than 45years of age were found to benefit most from TPC.
Source: American Heart Journal - April 7, 2018 Category: Cardiology Source Type: research
GlycA and hsCRP are Independent and Additive Predictors of Future Cardiovascular Events Among Patients Undergoing Angiography: The Intermountain Heart Collaborative Study
Conclusion In this study, levels of GlycA and hsCRP were independent and additive markers of risk for MACE, death and HF hospitalization.
Source: American Heart Journal - April 6, 2018 Category: Cardiology Source Type: research
Randomized placebo controlled trial evaluating the safety and efficacy of single low dose intracoronary insulin like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI)
Conclusion In this pilot trial, low dose IGF1, given after optimal mechanical reperfusion in STEMI, is safe but does not improve LVEF. However, there is a signal for a dose dependent benefit on post MI remodeling that may warrant further study.
Source: American Heart Journal - April 3, 2018 Category: Cardiology Source Type: research
Design and Rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) Trial
Conclusion CAMELLIA-TIMI 61 is investigating the safety and efficacy of lorcaserin for major adverse cardiovascular events and conversion to diabetes in overweight or obese patients with established cardiovascular disease or multiple cardiovascular risk factors.
Source: American Heart Journal - March 30, 2018 Category: Cardiology Source Type: research
